Imunon, Inc. (NASDAQ:IMNN) Short Interest Down 60.8% in May

Posted by on Jun 14th, 2026

Imunon, Inc. (NASDAQ:IMNN – Get Free Report) was the recipient of a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 57,617 shares, a drop of 60.8% from the May 14th total of 146,860 shares. Based on an average trading volume of 64,055 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.4% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IMNN. Maxim Group set a $10.00 target price on Imunon and gave the company a “buy” rating in a report on Friday, April 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

Get Our Latest Research Report on IMNN

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in shares of Imunon during the fourth quarter worth about $1,017,000. DRW Securities LLC increased its position in shares of Imunon by 6.9% during the fourth quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock worth $224,000 after acquiring an additional 3,803 shares during the last quarter. Finally, Riverview Capital Advisers LLC increased its position in shares of Imunon by 193.3% during the third quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after acquiring an additional 22,649 shares during the last quarter. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Trading Down 0.5%

Shares of IMNN traded down $0.01 during midday trading on Friday, reaching $2.02. 46,023 shares of the company were exchanged, compared to its average volume of 54,805. The stock has a 50-day moving average price of $2.60 and a 200-day moving average price of $3.16. The company has a market cap of $8.48 million, a price-to-earnings ratio of -0.39 and a beta of 1.95. Imunon has a 1-year low of $1.93 and a 1-year high of $20.48.

Imunon (NASDAQ:IMNN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.38. Equities research analysts anticipate that Imunon will post -3.46 earnings per share for the current year.

Imunon Company Profile

(Get Free Report)

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

Read More

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.